Genomic Vision appoints Mark David Lynch as Global Commercial and Marketing Director

BAGNEUX, France--(BUSINESS WIRE)--Regulatory News:

Genomic Vision (Paris:GV)(the “Company” - FR0011799907 – GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announces the appointment of Mark David Lynch as Global Commercial and Marketing Director.

Graduated in microbiology from University of Glasgow, Mark David Lynch has extensive experience in the business development of research and diagnostic devices.

Prior to joining Genomic Vision, Mark spent nearly 10 years at Fluidigm Corporation, a US biotechnology company, where he held different senior management positions, before becoming Head of Sales & Support. He was instrumental in the Company’s expansion, with substantial contribution to the growth of its microfluids business in the US market in 2020. During his career at Fluidigm, Mark has received several performance-related company awards.

Mark began his career in 2003 as Molecular Biology Technician at University of Glasgow, and, before joining Fluidigm in 2011, he worked as Field Application Specialist at Applied Biosystems and Account Manager for Molecular Biology instruments at Life Technologies.

“Integrating a company as innovative as Genomic Vision, with a high-potential technology in the field of research and diagnostics, is particularly stimulating. I’m glad to contribute with my 15 years of experience to the commercial and marketing development of the company,” said Mark Lynch, Global Commercial and Marketing Director of Genomic Vision.

Dominique Remy-Renou, CEO of Genomic Vision, added: “I am delighted that Mark Lynch has joined Genomic Vision as Global Commercial and Marketing Director. Having Mark with us will directly contribute to our company’s strategy to develop and commercialize new applications by molecular combing, essentially into different sectors of the healthcare market. The success of our new portfolio of Services has recently demonstrated the interest of the market in our technology. We look forward to the cooperation with Mark to further expand our presence in the field.”

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed to high confidence characterization of DNA alteration in the genome. These tools are mainly used for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Genomic Vision, based near Paris in Bagneux, is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

For further information, please visit www.genomicvision.com.

Member of the CAC^® Mid & Small and CAC^® All-Tradable indexes

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the universal registration document filed with the AMF on February 9, 2021 under reference number R.21-002, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

Genomic Vision
Dominique Remy-Renou
CEO
Tel.: +33 1 49 08 07 51
investisseurs@genomicvision.com

Ulysse Communication
Press Relations
Bruno Arabian
Tel.: +33 1 42 68 29 70
barabian@ulysse-communication.com

NewCap
Investor Relations
& Strategic Communications
Tel.: +33 1 44 71 94 94
gv@newcap.eu